Ocular inflammatory events following COVID-19 vaccination: reporting of suspected adverse drug reactions to regulatory authorities in the UK.
Ilaria TestiTaha SoomroCarlos PavesioAmeenat Lola SoleboPublished in: The British journal of ophthalmology (2023)
Ocular inflammatory events following COVID-19 vaccination have a very rare prevalence in the UK. There is no increase in the reporting rate of uveitis, optic neuritis and scleritis following COVID-19 vaccination when compared with the range of incidence in the UK population. The Yellow Card System represents a vital instrument within the domain of pharmacovigilance, empowering patients and healthcare professionals to contribute to the ongoing monitoring of medication safety.
Keyphrases
- adverse drug
- coronavirus disease
- sars cov
- electronic health record
- emergency department
- end stage renal disease
- risk factors
- cross sectional
- oxidative stress
- drug induced
- ejection fraction
- chronic kidney disease
- newly diagnosed
- patient reported outcomes
- optic nerve
- respiratory syndrome coronavirus
- prognostic factors
- juvenile idiopathic arthritis
- ankylosing spondylitis